Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Nov 07 04:00PM ET
3.85
Dollar change
-0.10
Percentage change
-2.53
%
IndexRUT P/E- EPS (ttm)- Insider Own17.74% Shs Outstand26.88M Perf Week-1.03%
Market Cap103.79M Forward P/E- EPS next Y-2.87 Insider Trans0.31% Shs Float22.18M Perf Month-65.90%
Income- PEG- EPS next Q-0.65 Inst Own68.18% Short Float24.13% Perf Quarter-54.06%
Sales- P/S- EPS this Y72.85% Inst Trans30.03% Short Ratio7.60 Perf Half Y-73.63%
Book/sh6.67 P/B0.58 EPS next Y-8.53% ROA- Short Interest5.35M Perf Year-
Cash/sh7.16 P/C0.54 EPS next 5Y- ROE- 52W Range3.61 - 24.00 Perf YTD-81.40%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-83.96% Beta-
Dividend TTM- Quick Ratio19.85 Sales past 5Y-50.00% Gross Margin- 52W Low6.65% ATR (14)0.84
Dividend Ex-Date- Current Ratio19.85 EPS Y/Y TTM- Oper. Margin- RSI (14)24.29 Volatility7.59% 8.96%
Employees63 Debt/Eq0.06 Sales Y/Y TTM- Profit Margin- Recom1.71 Target Price16.41
Option/ShortYes / Yes LT Debt/Eq0.04 EPS Q/Q-198166.67% Payout- Rel Volume1.21 Prev Close3.95
Sales Surprise- EPS Surprise8.63% Sales Q/Q- EarningsAug 13 AMC Avg Volume704.36K Price3.85
SMA20-52.42% SMA50-64.01% SMA200-69.67% Trades Volume855,619 Change-2.53%
Date Action Analyst Rating Change Price Target Change
Oct-23-24Downgrade Wedbush Outperform → Neutral $29 → $4
Oct-23-24Downgrade Rodman & Renshaw Buy → Neutral
Sep-03-24Initiated Wedbush Outperform $29
Feb-27-24Initiated William Blair Outperform
Feb-27-24Initiated TD Cowen Outperform
Feb-27-24Initiated Stifel Buy $32
Feb-27-24Initiated Robert W. Baird Outperform $32
Feb-27-24Initiated Jefferies Buy $33
Nov-04-24 08:00AM
Oct-24-24 08:32AM
Oct-23-24 01:36PM
08:03AM
07:32AM
04:30PM Loading…
Oct-22-24 04:30PM
Sep-05-24 09:27AM
Sep-04-24 08:05AM
Sep-03-24 08:05AM
Aug-13-24 04:05PM
Jul-25-24 08:30AM
Jul-16-24 07:30AM
Jul-12-24 01:58PM
Jun-20-24 08:05AM
Jun-18-24 08:05AM
09:00AM Loading…
Jun-10-24 09:00AM
May-29-24 08:05AM
May-21-24 08:05AM
May-14-24 10:54PM
04:03PM
May-09-24 08:05AM
Apr-23-24 08:05AM
Apr-10-24 03:30PM
Apr-09-24 09:37AM
Apr-03-24 08:05AM
Mar-21-24 04:05PM
Mar-11-24 08:05AM
Mar-07-24 08:00AM
Feb-27-24 08:00AM
Feb-06-24 04:05PM
08:57PM Loading…
Feb-01-24 08:57PM
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Savitz AdamCHIEF MEDICAL OFFICERJul 09 '24Buy12.6012,069152,08536,920Jul 11 04:15 PM
Savitz AdamCHIEF MEDICAL OFFICERJul 10 '24Buy13.222,93138,74839,851Jul 11 04:15 PM
Smith Nicholas ConradCHIEF FINANCIAL OFFICERMar 28 '24Buy16.366,150100,62826,866Apr 01 04:15 PM
Alpha Wave Global, LP10% OwnerFeb 06 '24Buy16.00600,0009,600,0003,707,757Feb 08 04:32 PM
Smith Nicholas ConradCHIEF FINANCIAL OFFICERFeb 06 '24Buy16.001,56325,0081,563Feb 07 04:40 PM
Savitz AdamCHIEF MEDICAL OFFICERFeb 06 '24Buy16.0017,000272,00024,851Feb 07 04:38 PM
Etkin AmitPRESIDENT AND CEOFeb 06 '24Buy16.003,12550,0001,205,465Feb 07 04:36 PM